Business Context and Reporting Period
Company: Arvinas, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2025
Principal Event: Announcement of U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application (NDA) for vepdegestrant.
Key Financial Metrics
This filing is a current report regarding a regulatory milestone and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material change reported is the regulatory status of the company's lead asset:
- Regulatory Acceptance: The FDA has accepted the NDA for vepdegestrant.
- Indication: Treatment of patients with estrogen receptor positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) ESR1-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy.
- Timeline: The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of June 5, 2026.
Outlook, Risks, and Management Commentary
Outlook: The acceptance of the NDA initiates the formal FDA review process with a target decision date in mid-2026. This represents a critical step toward potential commercialization for the specified breast cancer indication.
Risks and Contingencies: While the NDA has been accepted, the filing does not guarantee approval. The company remains subject to the standard risks associated with clinical development and regulatory review, including the possibility of the FDA requesting additional information or denying the application prior to the PDUFA date.
Investor Verification Checklist
- Verify the specific patient population criteria (ER+/HER2- ESR1-mutated) for the NDA approval.
- Monitor the FDA PDUFA action date of June 5, 2026, for the final approval decision.
- Review the full text of the press release (Exhibit 99.1) for any additional clinical data or management commentary not summarized in the 8-K.
- Check subsequent filings for any FDA Complete Response Letters or requests for additional data prior to the action date.